ストックスクリーナーアプリを入手
11.45
2.97%
-0.35
Dyne Therapeutics Inc (DYN) 最新ニュース
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
Dyne names Editas’ Erick Lucera CFO - BioCentury
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga India
Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com
JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review
Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa
Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com
Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks
Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com
Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire
New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan
Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan
(DYN) Technical Data - Stock Traders Daily
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN
Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com
Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - Marketscreener.com
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect - BioSpace
Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq
Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq
Game-Changing DMD Clinical Trial: Dyne's DYNE-251 Achieves 8.72% Dystrophin Expression - StockTitan
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World
Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia
Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com
Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa
Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com India
GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail
Dyne: Accelerated Approval DYNE-101 Might Be Possible With Surrogate Biomarker (DYN) - Seeking Alpha
BMO Capital Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Yahoo Finance
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating - Yahoo Finance
BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target -March 12, 2025 at 07:22 am EDT - Marketscreener.com
Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating - TipRanks
Dyne Therapeutics initiated with an Outperform at BMO Capital - TipRanks
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum - GlobeNewswire
Neuromuscular Disease Breakthroughs: Dyne Therapeutics Reveals Latest Progress at CNS Forum - StockTitan
Dyne Therapeutics (NASDAQ:DYN) Research Coverage Started at Scotiabank - Defense World
Critical Analysis: Dyne Therapeutics (NASDAQ:DYN) and Lantern Pharma (NASDAQ:LTRN) - Defense World
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Scotiabank - MarketBeat
Scotiabank Initiates Coverage of Dyne Therapeutics (DYN) with Sector Outperform Recommendation - Nasdaq
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Thinking Of Investing In Dyne Therapeutics Inc (NASDAQ: DYN) Stock? Read This First - Stocks Register
Scotiabank sets Dyne Therapeutics stock target at $50, cites entry point - Investing.com India
Dyne Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Y Intercept Hong Kong Ltd Has $230,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.4% on Analyst Downgrade - Defense World
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):